If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
==== United States ==== 1S-LSD is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
=== Geographical territories === In the United States, the common blue violet Viola sororia is the state flower of Illinois, Rhode Island, New Jersey and Wisconsin. In Canada, the Viola cucullata is the provincial flower of New Brunswick, adopted in 1936. In the United Kingdom, Viola riviniana is the county flower of Lincolnshire.
== Causes == Myxedema coma represents an extreme or decompensated form of hypothyroidism. Most cases occur in patients who have been previously diagnosed with hypothyroidism, yet in some cases, hypothyroidism may not have been previously identified. Common precipitating factors of myxedema coma include:
Sources: en.wikipedia.org
== Comparative structure == The structure of the sarcomere affects its function in several ways. The overlap of actin and myosin gives rise to the length-tension curve, which shows how sarcomere force output decreases if the muscle is stretched so that fewer cross-bridges can form or compressed until actin filaments interfere with each other. Length of the actin and myosin filaments (taken together as sarcomere length) affects force and velocity – longer sarcomeres have more cross-bridges and thus more force, but have a reduced range of shortening. Vertebrates display a very limited range of sarcomere lengths, with roughly the same optimal length (length at peak length-tension) in all muscles of an individual as well as between species. Arthropods, however, show tremendous variation (over seven-fold) in sarcomere length, both between species and between muscles in a single individual. The reasons for the lack of substantial sarcomere variability in vertebrates is not fully known.
== Career == After completing his doctorate, Al-Fawzan was appointed as a teacher at the Ma'had al-'Ilmī (Institute of Knowledge) at the Imam Muhammad ibn Saud Islamic University in Riyadh. He subsequently taught at Kullīyat al-Sharī'a (The College of Sharia), then transferred to teach in the postgraduate program at Kullīyat Uṣūl al-Dīn (College of Fundamentals of Religion), then at the Ma'had al-'Ālī li al-Qaḍā (Higher Institute of Judiciary), where he was later appointed director. He later served as the head of Saudi Arabia's Supreme Court of Justice before returning to teaching following the conclusion of his tenure. As of 2013, he was appointed as a member of the Council of Senior Scholars, Saudi Arabia's highest religious body, which directly advises the King of Saudi Arabia. He is also currently a member of the fiqh council in Mecca, which is affiliated with the Muslim World League, and of the Permanent Committee for Scholarly Research and Ifta, a subcommittee of the Council of Senior Scholars responsible for issuing legal opinions (fatwas) in Islamic jurisprudence (fiqh) and preparing research papers for the Council. Al-Fawzan serves on the Supervisory Committee for Preachers during Hajj and is an imam, khatib and teacher at the Prince Mutaib bin Abdulaziz Al Saud Mosque in Riyadh. He is one of the scholars featured on the Nūr 'Alā al-Darb radio program, described as one of the oldest and most famous programs broadcast on the Quran radio channel, where senior scholars answer questions and issue fatwas.
MRI is used industrially mainly for routine analysis of chemicals. The nuclear magnetic resonance technique is also used, for example, to measure the ratio between water and fat in foods, monitoring of flow of corrosive fluids in pipes, or to study molecular structures such as catalysts. Being non-invasive and non-damaging, MRI can be used to study the anatomy of plants, their water transportation processes and water balance. It is also applied to veterinary radiology for diagnostic purposes. Outside this, its use in zoology is limited due to the high cost; but it can be used on many species. In palaeontology it is used to examine the structure of fossils. Forensic imaging provides graphic documentation of an autopsy, which manual autopsy does not. CT scanning provides quick whole-body imaging of skeletal and parenchymal alterations, whereas MR imaging gives better representation of soft tissue pathology. All that being said, MRI is more expensive, and more time-consuming to utilize. Moreover, the quality of MR imaging deteriorates below 10 °C.
Sources: en.wikipedia.org
=== Disease free survival === The disease free survival is usually used to analyze the results of the treatment for the localized disease which renders the patient apparently disease free, such as surgery or surgery plus adjuvant therapy. In the disease-free survival, the event is relapse rather than death. The people who relapse are still surviving but they are no longer disease-free. Just as in the survival curves not all patients die, in "disease-free survival curves" not all patients relapse and the curve may have a final plateau representing the patients who didn't relapse after the study's maximum follow-up. Because the patients survive for at least some time after the relapse, the curve for the actual survival would look better than disease free survival curve.
=== Hopback === A hopback is a traditional chamber between the brewing kettle and wort chiller that acts as a sieve or filter by using whole hops to clear debris (or "trub") from the unfermented wort, as the whirlpool does, and also to increase hop aroma in the finished beer. Hops are added to the chamber, the hot wort from the kettle is run through it, and then immediately cooled in the wort chiller before entering the fermentation vessel. Hopbacks utilising a sealed chamber facilitate maximum retention of volatile hop aroma compounds that would normally be driven off when the hops contact the hot wort. While a hopback has a similar filtering effect as a whirlpool, it operates differently: a whirlpool uses centrifugal forces, while a hopback uses a layer of whole hops to act as a filter bed. Whirlpools are particularly suited to the removal of pelleted hops, whereas hopbacks are generally used to remove whole flower hops from the wort, retaining them as a filter bed. The hopback has mainly been substituted in modern breweries by the whirlpool.
The death of Roosevelt, the end of the need for a wartime alliance against Germany, and the determination by American war planners that Soviet assistance in Manchuria would not be needed to defeat Japan, meant that the major barriers to disengaging with the Soviets had been eliminated. Following the Allied victory in May, the Soviets effectively occupied Eastern Europe, while the US had much of Western Europe. In occupied Germany, the US and the Soviet Union established zones of occupation and a loose framework for four-power control with the ailing French and British.
== History == MCH was initially discovered in the teleost fish; it was found to help determine the fish's skin color. Later, a mammalian version of MCH was discovered in rats, where most of the functions and localizations are conserved across mammalian species.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.